In Q1 FY2026 (ended March 31, 2026), Theravance Biopharma reported revenue of $17.7 million, up 15.0% year-over-year. Net loss narrowed to $4.9 million from $13.6 million a year ago, a 63.7% improvement. Operating loss improved 34.3% to $9.5 million. The company held $288.1 million in cash and $290.6 million in equity, with no long-term debt.
•Revenue grew 15.0% YoY to $17.7 million.
•Net loss improved 63.7% to $4.9 million.
•Operating loss improved 34.3% to $9.5 million.
•Cash and equity stood at $288.1 million and $290.6 million, respectively, with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Theravance Biopharma, Inc., a biopharmaceutical company develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD)
Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing medicines in the United States. Its primary marketed product is YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). The company also has an investigational drug, Ampreloxetine, which is a once-daily norepinephrine reuptake inhibitor currently in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). Additionally, Theravance Biopharma has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution.
Where is Theravance Biopharma (TBPH) listed and what currency does it trade in?
Theravance Biopharma, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol TBPH. Its shares are traded in United States Dollars (USD), as the company is based in the United States and its stock is listed on a U.S. exchange. The NasdaqGM is a tier of the Nasdaq Stock Market that lists companies meeting specific financial and liquidity requirements, providing investors with access to trade TBPH shares in a regulated environment.
What sector and industry does Theravance Biopharma (TBPH) belong to?
Theravance Biopharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies for medical conditions. Its work involves leveraging biological processes to create drugs, such as YUPELRI for COPD and Ampreloxetine for nOH in MSA patients. The biotechnology industry is characterized by high research and development costs, regulatory approvals, and a focus on addressing unmet medical needs.
Where is Theravance Biopharma headquartered and what markets does it serve?
Theravance Biopharma, Inc. is headquartered in South San Francisco, California, United States. The company primarily serves the U.S. market, as indicated by its focus on developing and commercializing medicines in the United States. Its marketed product YUPELRI is available for patients with COPD in the U.S., and its investigational drug Ampreloxetine is being studied for a condition that affects patients in the U.S. and globally. The company was incorporated in 2013 and has since concentrated its operations on the U.S. healthcare market.
How does Theravance Biopharma (TBPH) make money?
Theravance Biopharma generates revenue primarily through the commercialization of its approved medicine YUPELRI, a nebulized treatment for COPD. The company also has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, which includes YUPELRI. This partnership likely provides Theravance with milestone payments, royalties, or profit-sharing from sales. Additionally, the company may receive funding or payments related to its investigational drug Ampreloxetine as it progresses through clinical trials. As a biotech firm, its business model relies on successful drug development, regulatory approvals, and commercial partnerships to generate income.